| 篇名 |
The clinical significance of ARID1A mutations in gastric cancer patients |
| 作者 |
Chia‑Hung Wu, Chien‑Hsun Tseng, Kuo‑Hung Huang, Wen‑Liang Fang, Ming‑Huang Chen, Anna Fen‑Yau Li, Chew‑Wun Wu |
| 卷期/出版年月 |
53卷3期 (2020/6) |
| 頁次 |
93-100 |
| 摘要 |
Background: ARID1A is a key component of the SWI/SNF chromatin remodeling complex, which has been identified in various cancers. Loss of ARID1A expression is correlated with poor prognosis in gastric cancer (GC); however, the clinical relevance of ARID1A mutations in GC has not yet been reported.
Materials and Methods: A total of 518 GC patients receiving gastrectomy were enrolled. The analysis of 13 mutations of the ARID1A gene using mass spectrometric single‑nucleotide polymorphism genotyping technology was conducted. The clinicopathological features of GC with and without ARID1A mutations were compared.
Results: Among the 518 GC patients, 59 (11.4%) had ARID1A mutations. For diffuse‑type GC, patients with ARID1A‑mutated tumors were older and had fewer poorly differentiated tumors, fewer incidence of Epstein–Barr virus infection, a higher likelihood of ARID1A expression loss, more microsatellite instability‑high tumors, a lower prevalence of peritoneal recurrence, and better survival rates than those with ARID1A nonmutant tumors. For intestinal‑type GC, patients with ARID1A‑mutant tumors had more PI3K/AKT pathway genetic mutations than patients with ARID1A nonmutant tumors. Multivariate analysis showed that ARID1A mutations are an independent prognostic factor in diffuse‑type GC.
Conclusion: ARID1A mutations are associated with a better prognosis in diffuse‑type GC. |
| 關鍵詞 |
ARID1A expression, ARID1A mutation, diffuse‑type, gastric cancer, prognostic factor |
| 分類 |
Original Article |
